These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

403 related items for PubMed ID: 28858176

  • 1. Midterm Outcomes of 12 Renal Transplant Recipients Treated With Eculizumab to Prevent Atypical Hemolytic Syndrome Recurrence.
    Levi C, Frémeaux-Bacchi V, Zuber J, Rabant M, Devriese M, Snanoudj R, Scemla A, Amrouche L, Mejean A, Legendre C, Sberro-Soussan R.
    Transplantation; 2017 Dec; 101(12):2924-2930. PubMed ID: 28858176
    [Abstract] [Full Text] [Related]

  • 2. Living Donor Kidney Transplantation in Atypical Hemolytic Uremic Syndrome: A Case Series.
    Duineveld C, Verhave JC, Berger SP, van de Kar NCAJ, Wetzels JFM.
    Am J Kidney Dis; 2017 Dec; 70(6):770-777. PubMed ID: 28821363
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of Eculizumab Therapy for Atypical Hemolytic Uremic Syndrome Recurrence and Antibody-Mediated Rejection Progress After Renal Transplantation With Preformed Donor-Specific Antibodies: Case Report.
    Yamamoto T, Watarai Y, Futamura K, Okada M, Tsujita M, Hiramitsu T, Goto N, Narumi S, Takeda A, Kobayashi T.
    Transplant Proc; 2017 Dec; 49(1):159-162. PubMed ID: 28104125
    [Abstract] [Full Text] [Related]

  • 4. Ten-year outcome of Eculizumab in kidney transplant recipients with atypical hemolytic uremic syndrome- a single center experience.
    Kant S, Bhalla A, Alasfar S, Alachkar N.
    BMC Nephrol; 2020 May 20; 21(1):189. PubMed ID: 32434487
    [Abstract] [Full Text] [Related]

  • 5. Prevention of recurrence of atypical hemolytic uremic syndrome post renal transplant with the use of higher-dose eculizumab
.
    Riddell A, Goodship T, Bingham C.
    Clin Nephrol; 2016 Oct 20; 86(10):200-2. PubMed ID: 27616760
    [Abstract] [Full Text] [Related]

  • 6. Atypical hemolytic uremic syndrome recurrence after kidney transplantation.
    Matar D, Naqvi F, Racusen LC, Carter-Monroe N, Montgomery RA, Alachkar N.
    Transplantation; 2014 Dec 15; 98(11):1205-12. PubMed ID: 24933457
    [Abstract] [Full Text] [Related]

  • 7. Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation.
    Zuber J, Le Quintrec M, Krid S, Bertoye C, Gueutin V, Lahoche A, Heyne N, Ardissino G, Chatelet V, Noël LH, Hourmant M, Niaudet P, Frémeaux-Bacchi V, Rondeau E, Legendre C, Loirat C, French Study Group for Atypical HUS.
    Am J Transplant; 2012 Dec 15; 12(12):3337-54. PubMed ID: 22958221
    [Abstract] [Full Text] [Related]

  • 8. Atypical haemolytic uraemic syndrome treated with the complement inhibitor eculizumab: the experience of the Australian compassionate access cohort.
    Mallett A, Hughes P, Szer J, Tuckfield A, Van Eps C, Cambell SB, Hawley C, Burke J, Kausman J, Hewitt I, Parnham A, Ford S, Isbel N.
    Intern Med J; 2015 Oct 15; 45(10):1054-65. PubMed ID: 26247170
    [Abstract] [Full Text] [Related]

  • 9. Isolated thrombotic microangiopathy of the small intestine in a patient with atypical hemolytic uremic syndrome - a case report.
    Nunius C, Büttner-Herold M, Bertz S, Schiffer M, Buchholz B.
    BMC Nephrol; 2020 Mar 24; 21(1):104. PubMed ID: 32204691
    [Abstract] [Full Text] [Related]

  • 10. Tailored eculizumab therapy in the management of complement factor H-mediated atypical hemolytic uremic syndrome in an adult kidney transplant recipient: a case report.
    Xie L, Nester CM, Reed AI, Zhang Y, Smith RJ, Thomas CP.
    Transplant Proc; 2012 Dec 24; 44(10):3037-40. PubMed ID: 23195022
    [Abstract] [Full Text] [Related]

  • 11. [Recurrent atypical hemolytic uremic syndrome after renal transplantation: treatment with eculizumab].
    Latzke AB, Fernández P, Chiurchiu C, Sarmantano D, De Arteaga J, Douthat W, De la Fuente J.
    Medicina (B Aires); 2018 Dec 24; 78(2):119-122. PubMed ID: 29659362
    [Abstract] [Full Text] [Related]

  • 12. Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases.
    Fakhouri F, Delmas Y, Provot F, Barbet C, Karras A, Makdassi R, Courivaud C, Rifard K, Servais A, Allard C, Besson V, Cousin M, Châtelet V, Goujon JM, Coindre JP, Laurent G, Loirat C, Frémeaux-Bacchi V.
    Am J Kidney Dis; 2014 Jan 24; 63(1):40-8. PubMed ID: 24021908
    [Abstract] [Full Text] [Related]

  • 13. Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome.
    Cugno M, Gualtierotti R, Possenti I, Testa S, Tel F, Griffini S, Grovetti E, Tedeschi S, Salardi S, Cresseri D, Messa P, Ardissino G.
    J Thromb Haemost; 2014 Sep 24; 12(9):1440-8. PubMed ID: 24853860
    [Abstract] [Full Text] [Related]

  • 14. Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders.
    Wehling C, Amon O, Bommer M, Hoppe B, Kentouche K, Schalk G, Weimer R, Wiesener M, Hohenstein B, Tönshoff B, Büscher R, Fehrenbach H, Gök ÖN, Kirschfink M.
    Clin Exp Immunol; 2017 Feb 24; 187(2):304-315. PubMed ID: 27784126
    [Abstract] [Full Text] [Related]

  • 15. Prevention and treatment of atypical haemolytic uremic syndrome after kidney transplantation.
    Okumi M, Tanabe K.
    Nephrology (Carlton); 2016 Jul 24; 21 Suppl 1():9-13. PubMed ID: 26988663
    [Abstract] [Full Text] [Related]

  • 16. Prophylactic Eculizumab Use in Kidney Transplantation: A Review of the Literature and Report of a Case with Atypical Hemolytic Uremic Syndrome.
    Kasapoğlu U, Ruhi Ç, Tuğcu M, Boynueğri B, Titiz İ, Hançer VS, Apaydın S.
    Ann Transplant; 2015 Dec 01; 20():714-9. PubMed ID: 26621268
    [Abstract] [Full Text] [Related]

  • 17. Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial.
    Fakhouri F, Hourmant M, Campistol JM, Cataland SR, Espinosa M, Gaber AO, Menne J, Minetti EE, Provôt F, Rondeau E, Ruggenenti P, Weekers LE, Ogawa M, Bedrosian CL, Legendre CM.
    Am J Kidney Dis; 2016 Jul 01; 68(1):84-93. PubMed ID: 27012908
    [Abstract] [Full Text] [Related]

  • 18. Adult Post-Kidney Transplant Familial Atypical Hemolytic Uremic Syndrome Successfully Treated With Eculizumab: A Case Report and Literature Review.
    Salameh H, Abu Omar M, Alhariri A, Kisra S, Qasem A, Abdulhak AB.
    Am J Ther; 2016 Jul 01; 23(4):e1110-5. PubMed ID: 25486517
    [Abstract] [Full Text] [Related]

  • 19. Thrombotic microangiopathy after kidney transplantation: Analysis of the Brazilian Atypical Hemolytic Uremic Syndrome cohort.
    Nga HS, Palma LMP, Ernandes Neto M, Fernandes-Charpiot IMM, Garcia VD, Kist R, Miranda SMC, Macedo de Souza PA, Pereira GM, de Andrade LGM.
    PLoS One; 2021 Jul 01; 16(11):e0258319. PubMed ID: 34748552
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of Eculizumab Use in Renal Transplant Recipients.
    Norville K, Stephen J, Mead-Harvey C, Corey R, Votruba C.
    Prog Transplant; 2023 Jun 01; 33(2):162-167. PubMed ID: 36940100
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.